Global Lung Cancer Liquid Biopsy Market By Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA, Cell-Free DNA), By Application (Small Cell Lung Cancer, Non-Small Cell Lung Cancer), By End-User (Diagnostic & Imaging Centers, Hospitals, Academics & Research Centers) By Region, Industry Analysis, Share, Growth, Trends, and Forecast, 2021-2028

Covid-19 Impact on Global Lung Cancer Liquid Biopsy Market

Type: PDF

Status: Published

Categories: Pharma & Healthcare

Report Code : PHC214031

No. of Pages : 318

The global lung cancer liquid biopsy market is expected to grow from USD 293 million in 2019 to USD 994.2 million by 2028 at a CAGR of 16.5% over the forecast period 2021-2028.

Market Overview:

Lung cancer liquid biopsy is a non-invasive substitute for surgical biopsies for the detection of molecular biomarkers. Liquid biopsy forms an integral part of precision medicine and has enormous diagnostic and treatment implications for oncology to bring radical clinical practice changes. It enables physicians to detect the event of a disease or a tumor by examining an easy blood sample.

It's used to seek out the efficacy of a string of therapy and detect cancer. The rising incidences of lung cancer are the driving factor of the global lung cancer liquid biopsy market.

Market Dynamics:

Drivers:

Growing prevalence of lung cancer

Rising awareness about the disease among the population

Restraints:

Availability of alternative techniques such asUse of telematics in mining machinery computed tomography (CT) and MRI

The higher cost of biopsy equipment setup

Key Market Players:

Biocept, Exosome Diagnostics, F. Hoffmann-La Roche, QIAGEN, Agena Bioscience, AccuraGen, BARD1, Bio-Rad Laboratories, Biodesix, Cancer Genetics, Circulogene, CellMax Life, CLEARBRIDGE BIOMEDICS, and Cynvenio Biosystems are some of the prominent players in the global lung cancer liquid biopsy market.

The market is segmented based on the below-mentioned segments:

On the Basis of Circulating Biomarkers: Revenue

o Circulating Tumor Cells

o Circulating Tumor DNA

o Cell-Free DNA

On the Basis of Application: Revenue

o Small Cell Lung Cancer

o Non-Small Cell Lung Cancer

On the Basis of Application: Revenue

o Diagnostic & Imaging Centers

o Hospitals

o Academics & Research Centers

On The Basis of Region: Revenue

North America

- U.S.A
- Canada
- Mexico

Europe

- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe

Asia Pacific

- China
- Japan
- India
- SEA
- Australia
- Rest Of APAC

South America

- Brazil
- Argentina
- Rest of South America

Middle East & Africa

- South Africa
- Saudi Arabia
- UAE
- Rest of MEA

Report Description

Year Consideration
- Base year – 2020
- Historic Year-2017-2019
- Forecast year- 2021 to 2028

The global lung cancer liquid biopsy market will be based on revenue and volume. The study covers the market share for segments, countries, regions, and players.

The regions evaluated for the global lung cancer liquid biopsy market are Europe, North America, Asia Pacific, South America, and Middle East & Africa. Furthermore, the regions are further analyzed at the country-level.

The report provides an in-depth pricing analysis, value chain analysis, industry road map, and micro and macro factors.

The research report further provides the attractiveness of lung cancer liquid biopsy and regions based on their growth rate (CAGR), market size, and attractiveness by analyzing present and future prospects to analyze market growth and development in the future.

Also, the study focuses on market-related driving forces, restraints, potential opportunities for the market, significant developments, and advancement that serve as a key potential for investors.

The study offers an extensive evaluation of Porter's five forces analysis, SWOT analysis, and PESTEL analysis to provide data and information related to the business.

Porter's five forces model is analyzed to understand the overall competitive scenario that prevails in the market. The SWOT analysis also identifies the positive as well as the negative characteristics of market development which influences the company’s growth and development to sustain and survive in the long run. The PESTEL analysis identifies the macro (external) forces affecting the organization.

The report includes a thorough analysis of the company profiles of major companies operating in the global lung cancer liquid biopsy market and a comparative evaluation based on their business overviews, product offering, geographic presence, market share, business strategy, recent developments, product development & innovations, joint ventures, partnerships, mergers & acquisitions, expansions, SWOT analysis, and key financial information. It helps in evaluating the overall competition present in the market scenario.

Request For Request Sample

To receive a sample copy of this report, please complete the form below

Full Name

Company Name

Designation/Position

Contact

Region/Country

Message

Kindly share your specific requirement (if any), so we can get back to you with a solution

TABLE OF CONTENTS
1. INTRODUCTION
1.1. OBJECTIVES OF THE STUDY
1.2. SCOPE OF THE STUDY
1.3. GEOGRAPHIC SCOPE
1.4. MARKET DEFINITION
1.5. CURRENCY CONSIDERATION
1.6. YEAR CONSIDERATION
2. RESEARCH METHODOLOGY AND ASSUMPTIONS
2.1. SECONDARY RESEARCH
2.2. PRIMARY RESEARCH
2.3. MARKET BREAKUP AND DATA TRIANGULATION
2.4. MARKET SIZE ESTIMATION
2.4.1. BOTTOM UP APPROACH
2.4.2. TOP DOWN APPROACH
2.5. ASSUMPTION
3. EXECUTIVE SUMMARY
3.1. KEY MARKET INSIGHTS
3.2. SEGMENTATION OUTLOOK
3.3. COMPANY OUTLOOK
4. PREMIUM INSIGHTS
4.1. IMPACT OF COVID-19 ON MARKET
4.2. INDUSTRY ROAD MAP
4.3. INDUSTRY TREND
4.4. INDUSTRY SWOT ANALYSIS
4.5. MARKET ATTRACTIVENESS ANALYSIS
4.5.1. MARKET ATTRACTIVENESS BY SEGMENTS
4.5.1.1. LUNG CANCER LIQUID BIOPSY MARKET ATTENTIVENESS BY CIRCULATING BIOMARKERS
4.5.1.2. LUNG CANCER LIQUID BIOPSY MARKET ATTENTIVENESS BY APPLICATION
4.5.1.3. LUNG CANCER LIQUID BIOPSY MARKET ATTENTIVENESS BY END-USER
4.5.2. MARKET ATTRACTIVENESS BY REGION
4.5.2.1. NORTH AMERICA LUNG CANCER LIQUID BIOPSY MARKET ATTENTIVENESS BY COUNTRY
4.5.2.2. EUROPE LUNG CANCER LIQUID BIOPSY MARKET ATTENTIVENESS BY COUNTRY
4.5.2.3. ASIA PACIFIC LUNG CANCER LIQUID BIOPSY MARKET ATTENTIVENESS BY COUNTRY
4.5.2.4. SOUTH AMERICA LUNG CANCER LIQUID BIOPSY MARKET ATTENTIVENESS BY COUNTRY
4.5.2.5. MIDDLE EAST AND AFRICA LUNG CANCER LIQUID BIOPSY MARKET ATTENTIVENESS BY COUNTRY
4.6. PORTER’S FIVE FORCES ANALYSIS
4.6.1. THREAT OF NEW ENTRANTS
4.6.2. THREAT OF SUBSTITUTES
4.6.3. BARGAINING POWER OF SUPPLIERS
4.6.4. BARGAINING POWER OF BUYERS
4.6.5. INTENSITY OF COMPETITIVE RIVALRY
4.7. VALUE CHAIN ANALYSIS
4.7.1. RESEARCH & DEVELOPMENT COMPANIES
4.7.2. RAW MATERIAL/ COMPONENT SUPPLIERS
4.7.3. PRODUCT MANUFACTURERS
4.7.4. DISTRIBUTORS AND RETAILERS
4.7.5. END-USER INDUSTRIES
4.7.6. POST-SALES SERVICE PROVIDERS
4.8. FACTORS AFFECTING THE MARKET
4.8.1. MACRO FACTORS AFFECTING THE MARKET
4.8.2. MICRO FACTORS AFFECTING THE MARKET
4.8.3. PESTEL ANALYSIS
4.9. YEAR ON YEAR GROWTH RATE OF LUNG CANCER LIQUID BIOPSY
4.10. LIST OF SUPPLIERS
4.11. LIST OF BUYERS
4.12. COUNTRY LEVEL ANALYSIS
4.13. RULES AND REGULATION
5. MARKET DYNAMICS
5.1. MARKET DRIVERS
5.1.1. GROWING PREVALENCE OF LUNG CANCER
5.1.2. RISING AWARENESS ABOUT THE DISEASE AMONG THE POPULATION
5.2. MARKET RESTRAINTS
5.2.1. AVAILABILITY OF ALTERNATIVE TECHNIQUESSUCH ASUSE OF TELEMATICS IN MINING MACHINERYCOMPUTED TOMOGRAPHY (CT) AND MRI
5.2.2. THE HIGHER COST OF BIOPSY EQUIPMENT SETUP
5.3. MARKET OPPORTUNITIES
5.4. MARKET CHALLENGES
6. GLOBAL LUNG CANCER LIQUID BIOPSY MARKET INSIGHTS AND FORECAST ANALYSIS, BY CIRCULATING BIOMARKERS - 2017-2028
6.1. KEY FINDINGS
6.2. CIRCULATING TUMOR CELLS
6.3. CIRCULATING TUMOR DNA
6.4. CELL-FREE DNA
7. GLOBAL LUNG CANCER LIQUID BIOPSY MARKET INSIGHTS AND FORECAST ANALYSIS, BY APPLICATION - 2017-2028
7.1. KEY FINDINGS
7.2. SMALL CELL LUNG CANCER
7.3. NON-SMALL CELL LUNG CANCER
8. GLOBAL LUNG CANCER LIQUID BIOPSY MARKET INSIGHTS AND FORECAST ANALYSIS, BY END-USER - 2017-2028
8.1. KEY FINDINGS
8.2. DIAGNOSTIC & IMAGING CENTERS
8.3. HOSPITALS
8.4. ACADEMICS & RESEARCH CENTERS
9. GLOBAL LUNG CANCER LIQUID BIOPSY MARKET INSIGHTS AND FORECAST ANALYSIS, BY REGIONAL - 2017-2028
9.1. KEY FINDINGS
9.2. NORTH AMERICA
9.3. EUROPE
9.4. ASIA PACIFIC
9.5. SOUTH AMERICA
9.6. MIDDLE EAST & AFRICA
10. NORTH AMERICA LUNG CANCER LIQUID BIOPSY MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
10.1. BY COUNTRY
10.1.1. U.S.
10.1.2. CANADA
10.1.3. MEXICO
11. EUROPE LUNG CANCER LIQUID BIOPSY MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
11.1. BY COUNTRY
11.1.1. GERMANY
11.1.2. U.K.
11.1.3. FRANCE
11.1.4. ITALY
11.1.5. SPAIN
11.1.6. SWEDEN
11.1.7. BELGIUM
11.1.8. TURKEY
11.1.9. RUSSIA
11.1.10. POLAND
11.1.11. SWITZERLAND
11.1.12. NETHERLANDS
11.1.13. REST OF EUROPE
12. ASIA PACIFIC LUNG CANCER LIQUID BIOPSY MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
12.1. BY COUNTRY
12.1.1.1. JAPAN
12.1.1.2. CHINA
12.1.1.3. INDIA
12.1.1.4. AUSTRALIA
12.1.1.5. SOUTH KOREA
12.1.1.6. MALAYSIA
12.1.1.7. INDONESIA
12.1.1.8. VIETNAM
12.1.1.9. NEW ZEALAND
12.1.1.10. PHILIPPINES
12.1.1.11. TAIWAN
12.1.1.12. SINGAPORE
12.1.1.13. REST OF ASIA-PACIFIC
13. SOUTH AMERICA LUNG CANCER LIQUID BIOPSY MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
13.1. BY COUNTRY
13.1.1.1. BRAZIL
13.1.1.2. ARGENTINA
13.1.1.3. CHILE
13.1.1.4. COLOMBIA
13.1.1.5. REST OF SOUTH AMERICA
14. MIDDLE EAST & AFRICA LUNG CANCER LIQUID BIOPSY MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
14.1. BY COUNTRY
14.1.1.1. SOUTH AFRICA
14.1.1.2. U.A.E.
14.1.1.3. SAUDI ARABIA
14.1.1.4. REST OF MIDDLE EAST AND AFRICA
15. COMPETITIVE LANDSCAPE
15.1. MARKET SHARE OF KEY PLAYERS IN POWER TOOL MARKET
15.1.1. GLOBAL MARKET SHARE ANALYSIS
15.1.2. NORTH AMERICA MARKET SHARE ANALYSIS
15.1.3. EUROPE MARKET SHARE ANALYSIS
15.1.4. ASIA PACIFIC MARKET SHARE ANALYSIS
15.1.5. SOUTH AMERICA MARKET SHARE ANALYSIS
15.1.6. MIDDLE EAST & AFRICA MARKET SHARE ANALYSIS
15.2. LEADERSHIP MAPPING
15.2.1. VISIONARY PLAYERS
15.2.2. INNOVATORS PLAYERS
15.2.3. DYNAMIC DIFFERENTIATORS
15.2.4. EMERGING COMPANIES
15.3. COMPETITIVE SCENARIO AND TRENDS
15.3.1. MERGERS & ACQUISITIONS
15.3.2. PRODUCT LAUNCHES AND DEVELOPMENTS
15.3.3. PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS
15.3.4. EXPANSIONS
16. COMPANY PROFILES
16.1.1. BIOCEPT
16.1.1.1. COMPANY OVERVIEW
16.1.1.2. COMPANY SNAPSHOT
16.1.1.3. FINANCIAL ANALYSIS
16.1.1.3.1. REVENUE ANALYSIS
16.1.1.3.2. SALES ANALYSIS
16.1.1.3.3. PRICE ANALYSIS
16.1.1.3.4. MARGIN ANALYSIS
16.1.1.4. GEOGRAPHICAL PRESENCE
16.1.1.4.1. NORTH AMERICA
16.1.1.4.2. EUROPE
16.1.1.4.3. ASIA PACIFIC
16.1.1.4.4. SOUTH AMERICA
16.1.1.4.5. MIDDLE EAST & AFRICA
16.1.1.5. PRODUCT PORTFOLIO
16.1.1.6. SWOT ANALYSIS
16.1.1.7. RECENT DEVELOPMENT
16.1.2. EXOSOME DIAGNOSTICS
16.1.3. F. HOFFMANN-LA ROCHE
16.1.4. QIAGEN
16.1.5. AGENA BIOSCIENCE
16.1.6. ACCURAGEN
16.1.7. BARD1
16.1.8. BIO-RAD LABORATORIES
16.1.9. BIODESIX
16.1.10. CANCER GENETICS
16.1.11. CIRCULOGENE
16.1.12. CELLMAX LIFE
16.1.13. CLEARBRIDGE BIOMEDICS
16.1.14. CYNVENIOBIOSYSTEMS
17. STRATEGIC RECOMMENDATIONS
LIST OF TABLE
1. RESEARCH ASSUMPTION
2. COVID-19 IMPACT ON MARKET
3. MAJOR DEVELOPMENTS BY VARIOUS COMPANIES
4. GLOBAL LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
5. GLOBAL SMALL CELL LUNG CANCER LIQUID BIOPSY MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
6. GLOBAL NON-SMALL CELL LUNG CANCER LIQUID BIOPSY MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
7. GLOBAL LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
8. GLOBAL CIRCULATING TUMOR CELLS LUNG CANCER LIQUID BIOPSY MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
9. GLOBAL CIRCULATING TUMOR DNA LUNG CANCER LIQUID BIOPSY MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
10. GLOBAL CELL-FREE DNA LUNG CANCER LIQUID BIOPSY MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
11. GLOBAL LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
12. GLOBAL DIAGNOSTIC & IMAGING CENTERS LUNG CANCER LIQUID BIOPSY , BY REGION, 2017–2028 REVENUE (USD MILLION)
13. GLOBAL HOSPITALS LUNG CANCER LIQUID BIOPSY , BY REGION, 2017–2028 REVENUE (USD MILLION)
14. GLOBAL ACADEMICS & RESEARCH CENTERS LUNG CANCER LIQUID BIOPSY MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
15. GLOBAL LUNG CANCER LIQUID BIOPSY MARKET, BY NORTH AMERICA, 2017–2028 REVENUE (USD MILLION)
16. NORTH AMERICA LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
17. NORTH AMERICA LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
18. NORTH AMERICA LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
19. U.S. LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
20. U.S. LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
21. U.S. LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
22. CANADA LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
23. CANADA LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
24. CANADA LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
25. MEXICO LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
26. MEXICO LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
27. MEXICO LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
28. EUROPE LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
29. EUROPE LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
30. EUROPE LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
31. GERMANY LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
32. GERMANY LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
33. GERMANY LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
34. FRANCE LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
35. FRANCE LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
36. FRANCE LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
37. U.K. LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
38. U.K. LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
39. U.K. LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
40. ITALY LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
41. ITALY LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
42. ITALY LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
43. SPAIN LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
44. SPAIN LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
45. SPAIN LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
46. SWEDEN LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
47. SWEDEN LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
48. SWEDEN LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
49. BELGIUM LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
50. BELGIUM LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
51. BELGIUM LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
52. TURKEY LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
53. TURKEY LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
54. TURKEY LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
55. RUSSIA LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
56. RUSSIA LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
57. RUSSIA LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
58. POLAND LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
59. POLAND LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
60. POLAND LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
61. SWITZERLAND LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
62. SWITZERLAND LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
63. SWITZERLAND LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
64. NETHERLANDS LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
65. NETHERLANDS LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
66. NETHERLANDS LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
67. ASIA PACIFIC LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
68. ASIA PACIFIC LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
69. ASIA PACIFIC LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
70. JAPAN LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
71. JAPAN LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
72. JAPAN LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
73. CHINA LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
74. CHINA LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
75. CHINA LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
76. INDIA LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
77. INDIA LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
78. INDIA LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
79. AUSTRALIA LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
80. AUSTRALIA LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
81. AUSTRALIA LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
82. SOUTH KOREA LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
83. SOUTH KOREA LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
84. SOUTH KOREA LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
85. INDONESIA LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
86. INDONESIA LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
87. INDONESIA LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
88. VIETNAM LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
89. VIETNAM LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
90. VIETNAM LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
91. NEW ZEALAND LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
92. NEW ZEALAND LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
93. NEW ZEALAND LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
94. PHILIPPINES LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
95. PHILIPPINES LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
96. PHILIPPINES LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
97. TAIWAN LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
98. TAIWAN LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
99. TAIWAN LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
100. SINGAPORE LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
101. SINGAPORE LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
102. SINGAPORE LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
103. SOUTH AMERICA LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
104. SOUTH AMERICA LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
105. SOUTH AMERICA LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
106. BRAZIL LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
107. BRAZIL LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
108. BRAZIL LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
109. ARGENTINA LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
110. ARGENTINA LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
111. ARGENTINA LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
112. CHILE LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
113. CHILE LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
114. CHILE LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
115. COLOMBIA LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
116. COLOMBIA LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
117. COLOMBIA LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
118. MIDDLE EAST AND AFRICA LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
119. MIDDLE EAST AND AFRICA LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
120. MIDDLE EAST AND AFRICA LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
121. UAE LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
122. UAE LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
123. UAE LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
124. SOUTH AFRICA LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
125. SOUTH AFRICA LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
126. SOUTH AFRICA LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
127. SAUDI ARABIA LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
128. SAUDI ARABIA LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
129. SAUDI ARABIA LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
130. REST OF MEA LUNG CANCER LIQUID BIOPSY MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
131. REST OF MEA LUNG CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2017–2028 REVENUE (USD MILLION)
132. REST OF MEA LUNG CANCER LIQUID BIOPSY MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)

LIST OF FIGURE
1. RESEARCH DESIGN
2. SCOPE OF THE STUDY
3. GEOGRAPHIC SCOPE
4. CURRENCY CONSIDERATION
5. YEAR CONSIDERATION
6. MARKET ESTIMATION
7. RESEARCH METHODOLOGY
8. DATA TRIANGULATION
9. COVID-19 IMPACT ON MARKET
10. GLOBAL LUNG CANCER LIQUID BIOPSY MARKET ATTRACTIVENESS ANALYSIS BY CIRCULATING BIOMARKERS
11. GLOBAL LUNG CANCER LIQUID BIOPSY MARKET ATTRACTIVENESS ANALYSIS BY APPLICATION
12. GLOBAL LUNG CANCER LIQUID BIOPSY MARKET ATTRACTIVENESS ANALYSIS BY END-USER
13. GLOBAL LUNG CANCER LIQUID BIOPSY MARKET ATTRACTIVENESS ANALYSIS BY REGION
14. GLOBAL LUNG CANCER LIQUID BIOPSY MARKET ATTRACTIVENESS ANALYSIS BY COUNTRY
15. GLOBAL LUNG CANCER LIQUID BIOPSY MARKET: DYNAMICS
16. PESTEL ANALYSIS
17. SWOT ANALYSIS
18. GLOBAL LUNG CANCER LIQUID BIOPSY MARKET ANALYSIS BY REGION
19. GLOBAL LUNG CANCER LIQUID BIOPSY MARKET ANALYSIS BY CIRCULATING BIOMARKERS
20. GLOBAL LUNG CANCER LIQUID BIOPSY MARKET ANALYSIS BY APPLICATION
21. GLOBAL LUNG CANCER LIQUID BIOPSY MARKET ANALYSIS BY END-USER
22. GLOBAL LUNG CANCER LIQUID BIOPSY MARKET ANALYSIS BY NORTH AMERICA
23. GLOBAL LUNG CANCER LIQUID BIOPSY MARKET ANALYSIS BY EUROPE
24. GLOBAL LUNG CANCER LIQUID BIOPSY MARKET ANALYSIS BY ASIA PACIFIC
25. GLOBAL LUNG CANCER LIQUID BIOPSY MARKET ANALYSIS BY SOUTH AMERICA
26. GLOBAL LUNG CANCER LIQUID BIOPSY MARKET ANALYSIS BY MIDDLE EAST & AFRICA
27. GLOBAL LUNG CANCER LIQUID BIOPSY MARKET SHARE BY COMPANY (2019)
28. NORTH AMERICA LUNG CANCER LIQUID BIOPSY MARKET SHARE BY COMPANY (2019)
29. EUROPE LUNG CANCER LIQUID BIOPSY MARKET SHARE BY COMPANY (2019)
30. ASIA PACIFIC LUNG CANCER LIQUID BIOPSY MARKET SHARE BY COMPANY (2019)
31. SOUTH AMERICA LUNG CANCER LIQUID BIOPSY MARKET SHARE BY COMPANY (2019)
32. MIDDLE EAST & AFRICA LUNG CANCER LIQUID BIOPSY MARKET SHARE BY COMPANY (2019)